Abstract:Our previous research has shown that monocytic leukemia-associated antigen-34 (MLAA-34) was a novel antiapoptotic molecule with unique expression in acute monocytic leukemia (M5), making it an ideal target for T-cell-based immunotherapy. Here, we sought to identify HLA-A*0201-restricted cytotoxic T-lymphocyte (CTL) epitope of MLAA-34 by reverse immunology. In all, 10 HLA-A*0201 restricted epitopes of MLAA-34 were predicted by bioinformatics. MLAA-34324-332, MLAA-34293-301, and MLAA-34236-244 showed the strongest HLA-A*0201-binding affinity. The percentages of HLA-A*0201-MLAA-34236-244 tetramer+ CD8+ T cells in MLAA-34236-244-induced CTLs were raised apparently. Enzyme-linked immunospot showed that MLAA-34236-244 and MLAA-34324-332-specific CTLs produced a higher amount of interferon-γ. MLAA-34236-244-induced CTLs presented a stronger cytotoxic effect on THP-1 cells (HLA-A*0201+MLAA-34+) at various effector to target ratios. MLAA-34236-244 peptide vaccine could inhibit the tumor growth and improve mean survival time of leukemia-bearing human peripheral blood lymphocyte reconstituting severe combined immunodeficient mice. Mice immunized with MLAA-34236-244 vaccine had increased percentages of MLAA-34236-244 tetramer+ CD8+ T cells in the spleen after each round of immunization. High-purity CD8+ and CD4+ T cells were sorted by Dynabeads as effector cells. The killing activity of CD8+ T cells was higher than that of CD4+ T cells. CTLs derived from the MLAA-34 peptide vaccine group were significantly higher than other therapeutic groups and showed specific cytotoxicity to THP-1 cells. Increased interferon-γ and interleukin (IL)-2 and decreased IL-10 and IL-4 were seen in the MLAA-34236-244 peptide vaccine group. MLAA-34236-244 peptide (ILDRHNFAI) is an effective HLA-A*0201-restricted CTL epitope and that it may serve as a promising strategy in designing antigen-specific immunotherapy against MLAA-34-positive acute monocytic leukemia.

Prediction and Identification of HLA-A*0201-restricted Epitopes from Leukemia-Associated Protein MLAA-22 Which Elicit Cytotoxic T Lymphocytes

Prediction and Identification of HLA-A2 Restricted CTL Epitope Derived from the Leukemia-Associated Antigen MLAA-34

Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia

Identification of predicted epitopes of HLA-A * 0201-restricted cytotoxic T lymphocytes derived from human papillomavirus type 11 E7 antigen

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28

Anti-Tumour and Immune Enhancing Activities of MLAA-22<sub>379–387</sub> on Acute Myeloid Leukemia

[Bioinformatic Analysis and Identification for a Novel Antigen MLAA-22 in Acute Monocytic Leukemia].

Anti-Tumour and Immune Enhancing Activities of MLAA-22379–387 on Acute Myeloid Leukemia

Prediction of HLA-A*0201 Restricted Cytotoxic T Lymphocyte Epitopes Based on High-Dimensional Descriptor Nonlinear Screening

Identification of Melanoma-Specific Peptide Epitopes by HLA-A2.1-restricted Cytotoxic T Lymphocytes.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Prediction, Synthesis and Identification of HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes of the Tumor Antigen MAGE-n

Identification of CD8+ T-cell Epitope from Multiple Myeloma-Specific Antigen AKAP4

Prediction and Peptide Binding Analysis of HLA-A*0201-restricted CTL Epitope from MUC4

Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Computational Prediction and Experimental Assessment of an HLA-A*0201-restricted Cytotoxic T Lymphocyte Epitope from Neutral Endopeptidase

Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

Identification of Two Novel Hla-A*0201-Restricted Ctl Epitopes Derived from Mage-A4